(0.27%) 5 145.25 points
(0.28%) 38 547 points
(0.38%) 17 914 points
(-0.78%) $83.20
(1.35%) $1.949
(-0.18%) $2 342.90
(1.09%) $27.55
(0.65%) $928.10
(-0.26%) $0.932
(-0.21%) $11.00
(-0.36%) $0.798
(0.87%) $92.67
-9.18% HKD 27.70
Live Chart Being Loaded With Signals
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States...
Stats | |
---|---|
Dagens volum | 2.25M |
Gjennomsnittsvolum | 2.55M |
Markedsverdi | 24.76B |
EPS | HKD0 ( 2023-10-30 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -9.14 |
ATR14 | HKD0.0800 (0.29%) |
Volum Korrelasjon
REMEGEN-B Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
REMEGEN-B Korrelasjon - Valuta/Råvare
REMEGEN-B Økonomi
Annual | 2023 |
Omsetning: | HKD1.08B |
Bruttogevinst: | HKD825.68M (76.24 %) |
EPS: | HKD-2.80 |
FY | 2023 |
Omsetning: | HKD1.08B |
Bruttogevinst: | HKD825.68M (76.24 %) |
EPS: | HKD-2.80 |
FY | 2022 |
Omsetning: | HKD767.78M |
Bruttogevinst: | HKD497.84M (64.84 %) |
EPS: | HKD-1.880 |
FY | 2021 |
Omsetning: | HKD1.42B |
Bruttogevinst: | HKD1.36B (95.28 %) |
EPS: | HKD0.680 |
Financial Reports:
No articles found.
REMEGEN-B
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.